MET Is highly expressed in advanced stages of colorectal cancer and indicates worse prognosis and mortality
Autor(a) principal: | |
---|---|
Data de Publicação: | 2009 |
Outros Autores: | , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | http://hdl.handle.net/1822/30089 |
Resumo: | The aim of the present study was to evaluate by immunohistochemistry the prognostic meaning of the tumor marker MET (hepatocyte growth factor) in patients submitted to surgical resection due to primary colorectal adenocarcinoma. PATIENTS AND METHODS: A retrospective study was carried out that included 286 consecutive patients with colorectal adenocarcinoma, submitted to surgical resection at Barretos Cancer Hospital, from 1993 to 2002. The histopathological expression of the MET tumor marker was evaluated using an anti-protein monoclonal antibody against MET by the streptavidin-biotin-peroxidase technique. The expression of the tumor marker was semi-quantitative, and the slide samples were independently analyzed by three pathologists unaware of patient clinical and histopathological data. RESULTS: The tumor marker expression was positive in 236 (79%) out of a total of 286 patients. This expression was statistically significantly different between stages I and IV (p=0.004), for overall survival (p=0.009), and for cancer-related mortality rates (p=0.022). However, no association between the tumor marker and recurrence (p=0.89) or disease-free interval (p=0.91) was observed. CONCLUSION: MET has shown significant expression at advanced stages of the disease, as well as for overall survival and cancer-related mortality rates demonstrating to be a valuable marker for poor prognosis in colorectal cancer patients. |
id |
RCAP_3ab206ff95187f18c5eac49fe1b2090b |
---|---|
oai_identifier_str |
oai:repositorium.sdum.uminho.pt:1822/30089 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
MET Is highly expressed in advanced stages of colorectal cancer and indicates worse prognosis and mortalityColorectal carcinomaimmunohistochemistryMETprognosissurvivalcarcinogenesisScience & TechnologyThe aim of the present study was to evaluate by immunohistochemistry the prognostic meaning of the tumor marker MET (hepatocyte growth factor) in patients submitted to surgical resection due to primary colorectal adenocarcinoma. PATIENTS AND METHODS: A retrospective study was carried out that included 286 consecutive patients with colorectal adenocarcinoma, submitted to surgical resection at Barretos Cancer Hospital, from 1993 to 2002. The histopathological expression of the MET tumor marker was evaluated using an anti-protein monoclonal antibody against MET by the streptavidin-biotin-peroxidase technique. The expression of the tumor marker was semi-quantitative, and the slide samples were independently analyzed by three pathologists unaware of patient clinical and histopathological data. RESULTS: The tumor marker expression was positive in 236 (79%) out of a total of 286 patients. This expression was statistically significantly different between stages I and IV (p=0.004), for overall survival (p=0.009), and for cancer-related mortality rates (p=0.022). However, no association between the tumor marker and recurrence (p=0.89) or disease-free interval (p=0.91) was observed. CONCLUSION: MET has shown significant expression at advanced stages of the disease, as well as for overall survival and cancer-related mortality rates demonstrating to be a valuable marker for poor prognosis in colorectal cancer patients.International Institute of Anticancer Research (IIAR)Universidade do MinhoOliveira, Antônio Talvane TorresMatos, DelcioLogullo, Angela FlavioSilva, Sandra Regina Morini daNeto, Ricardo ArtigianiLongatto Filho, AdhemarSaad, Sarhan Sydney20092009-01-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/1822/30089eng0250-700520032439http://ar.iiarjournals.org/content/29/11/4807.full.pdf+htmlinfo:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-07-21T12:45:32Zoai:repositorium.sdum.uminho.pt:1822/30089Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T19:43:23.914670Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
MET Is highly expressed in advanced stages of colorectal cancer and indicates worse prognosis and mortality |
title |
MET Is highly expressed in advanced stages of colorectal cancer and indicates worse prognosis and mortality |
spellingShingle |
MET Is highly expressed in advanced stages of colorectal cancer and indicates worse prognosis and mortality Oliveira, Antônio Talvane Torres Colorectal carcinoma immunohistochemistry MET prognosis survival carcinogenesis Science & Technology |
title_short |
MET Is highly expressed in advanced stages of colorectal cancer and indicates worse prognosis and mortality |
title_full |
MET Is highly expressed in advanced stages of colorectal cancer and indicates worse prognosis and mortality |
title_fullStr |
MET Is highly expressed in advanced stages of colorectal cancer and indicates worse prognosis and mortality |
title_full_unstemmed |
MET Is highly expressed in advanced stages of colorectal cancer and indicates worse prognosis and mortality |
title_sort |
MET Is highly expressed in advanced stages of colorectal cancer and indicates worse prognosis and mortality |
author |
Oliveira, Antônio Talvane Torres |
author_facet |
Oliveira, Antônio Talvane Torres Matos, Delcio Logullo, Angela Flavio Silva, Sandra Regina Morini da Neto, Ricardo Artigiani Longatto Filho, Adhemar Saad, Sarhan Sydney |
author_role |
author |
author2 |
Matos, Delcio Logullo, Angela Flavio Silva, Sandra Regina Morini da Neto, Ricardo Artigiani Longatto Filho, Adhemar Saad, Sarhan Sydney |
author2_role |
author author author author author author |
dc.contributor.none.fl_str_mv |
Universidade do Minho |
dc.contributor.author.fl_str_mv |
Oliveira, Antônio Talvane Torres Matos, Delcio Logullo, Angela Flavio Silva, Sandra Regina Morini da Neto, Ricardo Artigiani Longatto Filho, Adhemar Saad, Sarhan Sydney |
dc.subject.por.fl_str_mv |
Colorectal carcinoma immunohistochemistry MET prognosis survival carcinogenesis Science & Technology |
topic |
Colorectal carcinoma immunohistochemistry MET prognosis survival carcinogenesis Science & Technology |
description |
The aim of the present study was to evaluate by immunohistochemistry the prognostic meaning of the tumor marker MET (hepatocyte growth factor) in patients submitted to surgical resection due to primary colorectal adenocarcinoma. PATIENTS AND METHODS: A retrospective study was carried out that included 286 consecutive patients with colorectal adenocarcinoma, submitted to surgical resection at Barretos Cancer Hospital, from 1993 to 2002. The histopathological expression of the MET tumor marker was evaluated using an anti-protein monoclonal antibody against MET by the streptavidin-biotin-peroxidase technique. The expression of the tumor marker was semi-quantitative, and the slide samples were independently analyzed by three pathologists unaware of patient clinical and histopathological data. RESULTS: The tumor marker expression was positive in 236 (79%) out of a total of 286 patients. This expression was statistically significantly different between stages I and IV (p=0.004), for overall survival (p=0.009), and for cancer-related mortality rates (p=0.022). However, no association between the tumor marker and recurrence (p=0.89) or disease-free interval (p=0.91) was observed. CONCLUSION: MET has shown significant expression at advanced stages of the disease, as well as for overall survival and cancer-related mortality rates demonstrating to be a valuable marker for poor prognosis in colorectal cancer patients. |
publishDate |
2009 |
dc.date.none.fl_str_mv |
2009 2009-01-01T00:00:00Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/1822/30089 |
url |
http://hdl.handle.net/1822/30089 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
0250-7005 20032439 http://ar.iiarjournals.org/content/29/11/4807.full.pdf+html |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
International Institute of Anticancer Research (IIAR) |
publisher.none.fl_str_mv |
International Institute of Anticancer Research (IIAR) |
dc.source.none.fl_str_mv |
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
|
_version_ |
1799132990866980864 |